- Mylan Specialty announces winners of anaphylaxis awareness campaign
- Reports: Bill to extend federal regulations for compounding pharmacies expected to pass House, Senate
- Ensuring access to chronic pain medications
- Mylan launches generic version of Detrol LA
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
NEW YORK — New legislation signed into law Wednesday encourages states to adopt laws allowing schools to maintain a supply of emergency treatments for life-threatening allergy attacks.
Barack Obama signed the School Access to Emergency Epinephrine Act, under which schools could maintain a supply of epinephrine, which is the only first-line treatment for life-threatening allergic reactions, also known as anaphylaxis.
The legislation received praise from Mylan, a drug maker that produces EpiPen, a popular epinephrine injector pen.
"Recent tragedies have reinforced that when anaphylaxis occurs, every minute matters, and immediate access to epinephrine and emergency medical care is crucial," Mylan CEO Heather Bresch said. "The new federal law is a critical step for improving anaphylaxis preparedness in schools. We applaud those who worked tirelessly to make this bill a reality, from Congress, government officials and leading advocacy organizers to parents, caregivers, patients and healthcare professionals."